On October 5, 2022 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022 (Press release, Oncolytics Biotech, OCT 5, 2022, View Source [SID1234621721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Both abstracts will be published by SITC (Free SITC Whitepaper) at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below.

Title: Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Interim results from the GOBLET study
Abstract Number: 650
Poster Session Date and Time: November 11, 2022 from 9:00 a.m. – 8:30 p.m. ET
Poster Session Location: Boston Convention and Exhibition Center, Hall C

Title: The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study
Abstract Number: 548
Poster Session Date and Time: November 11, 2022 from 9:00 a.m. – 8:30 p.m. ET
Poster Session Location: Boston Convention and Exhibition Center, Hall C

Key Opinion Leader Webinar on Pancreatic Cancer and Interim Phase 1/2 GOBLET Study Data
Oncolytics will host a key opinion leader (KOL) webinar to discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as the interim GOBLET study results that will be presented at the SITC (Free SITC Whitepaper) conference on November 14, 2022 at 10 a.m. ET. The webinar will include both formal presentations and a live question and answer session.

To register for the webinar, please click here.

About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:

1.Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line advanced/metastatic pancreatic cancer patients (n=12);

2.Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients (n=19);

3.Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients (n=14); and

4.Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients (n=10).

Any cohort showing an ORR above a pre-specified threshold in Stage 1 may be advanced to Stage 2 and enroll additional patients.

On October 5, 2022 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that results from the Company’s ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the Manocept platform have been accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) ("SITC") to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA (Press release, Navidea Biopharmaceuticals, OCT 5, 2022, View Source [SID1234621720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, "Synthetic CD206 Targeted Constructs Carrying Paclitaxel or Novel Bisphosphonate Payloads Alter Macrophages Towards Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the Efficacy of anti-CTLA4 in CT26 Tumors" (Abstract #1161), will be presented as a poster on November 10, 9 am to 9 pm in the conference center’s poster hall. Further details of the abstract will be announced in a future press release once the meeting embargo is lifted.

Abstract title and session information can be found on the SITC (Free SITC Whitepaper) Annual Meeting website at: View Source

Dr. Michael Rosol, Chief Medical Officer for Navidea, said, "We are delighted by the opportunity to present these important preclinical results at this internationally recognized meeting." Dr. Rosol continued, "We continue to develop the Manocept platform, using its potent ability to target macrophages, for the development of new immunotherapies for diseases including cancer."

On October 5, 2022 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, reported that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) taking place in Boston, Nov. 8 – Nov. 12, 2022 (Press release, Lyell Immunopharma, OCT 5, 2022, View Source [SID1234621719]). The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells. The combination of these two genetic reprogramming technologies is being incorporated in Lyell’s new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our presence at SITC (Free SITC Whitepaper) includes presentations of new preclinical data from both existing and new reprogramming technologies being deployed in our growing pipeline of therapeutic candidates for solid tumors," stated Dr. Gary Lee, chief scientific officer at Lyell. "We look forward to sharing these preclinical findings on the potential of Lyell’s reprogramming technologies that are designed to address primary barriers to successful adoptive cell therapy in solid tumors in order to improve clinical responses in patients."

All the presentations describe preclinical data demonstrating that genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities, including CAR T cells, tumor-infiltrating lymphocytes (TILs) and T-cell receptor (TCR) T cells. Two presentations will feature preclinical data from LYL845, Lyell’s autologous TIL product candidate enhanced with Epi-R reprogramming technology, designed to create products with higher proportions of stem-like T cells. Lyell will also present preclinical data from its new genetic reprogramming technology designed to further limit T cell exhaustion, as well as data on its new epigenetic reprogramming technology, Stim-R, designed to generate a more potent T cell product by controlling delivery of activation molecules during T cell production.

Details on the five poster presentations are below:

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Category: Cellular therapies – Chimeric Antigen Receptors
Presentation Date, Time & Location: Thursday, Nov. 10, Poster Hall
Abstract No.: 243
Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R technology, a programmable synthetic cell-signaling platform

Category: Cellular Therapies – Chimeric Antigen Receptors
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 252
The Epi-R technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

Category: Cellular therapies – Non-CAR adoptive cell therapies
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 340
The Epi-R technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Category: Cellular therapies – Non-CAR adoptive cell therapies
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 370
Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R genetic reprogramming technology

Category: Cellular therapies – Non-CAR Adoptive Cell therapies
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 232

On October 5, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting in Boston, Massachusetts, November 8-12, 2022 (Press release, Iovance Biotherapeutics, OCT 5, 2022, View Source [SID1234621718]). The details of the posters and presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)
Authors: A. Sarnaik, et al
Presentation Type: Rapid Oral Abstracts and Poster
Session Date and Time: November 10, 2022, Concurrent Session 105 (11:55 a.m. – 12:55 p.m. ET) and Poster Hall (1 p.m. – 9:00 p.m. ET)
Abstract ID: 789

Title: Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Authors: A. Betof Warner, et al
Presentation Type: Poster
Session Date and Time: November 10, 2022, 9:00 a.m. – 9:00 p.m. ET, Poster Hall
Abstract ID: 783

Iovance will host a webcast and conference call on Thursday, November 10, 2022 at 4:30 p.m. ET to discuss the pooled analysis of Cohorts 2 and 4 of the C-144-01 study of lifileucel in advanced melanoma. Iovance senior leadership will be joined by key opinion leaders and principal investigators. The live and archived webcast will be available in the Investors section of the company’s website at www.iovance.com.

On October 5, 2022 IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, reported that it will present preclinical data on ICVB-1042 in three poster presentations at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2022), which is being held in Boston, MA and virtually from November 8-12, 2022 (Press release, IconOVir Bio, OCT 5, 2022, View Source [SID1234621716]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ICVB-1042, IconOVir’s lead product candidate, is a potent, replicative and systemically available OV. In preclinical studies, ICVB-1042 demonstrated superior potency and selectivity compared to wildtype adenovirus (Ad) and other clinical-stage Ad-based oncolytic viruses, with potent lytic replication in cancer cell lines across a broad range of tumor types. IconOVir is developing both intravenous (IV) and intratumoral (IT) formulations of ICVB-1042 and plans to advance into Phase 1 studies evaluating IV-administered ICVB-1042 in solid tumors in the first half of 2023.

Details of the poster presentations are as follows:

Abstract Title: Evaluation of the anti-tumor activity of ICVB-1042, a novel E2F-tumor selective oncolytic virus, selectively targeting tumor cells in an established human glioblastoma mouse model
Abstract Number: 1363
Session Date and Time: Thursday, November 10, 2022, 9:00 a.m. – 9:00 p.m. ET

Abstract Title: Nonclinical characterization of ICVB-1042, a novel E2F-tumor selective oncolytic virus with the potential to treat solid tumors
Abstract Number: 1362
Session Date and Time: Friday, November 11, 2022, 9:00 a.m. – 8:30 p.m. ET

Abstract Title: The chimeric Ad5/Ad34 fiber of ICVB-1042 oncolytic virus requires the CD46 cell surface receptor for efficient tumor entry
Abstract Number: 1216
Session Date and Time: Friday, November 11, 2022, 9:00 a.m. – 8:30 p.m. ET

Each abstract will become available online on the SITC (Free SITC Whitepaper) conference website beginning at 8:00 a.m. ET on Monday, November 7, 2022. For additional information, please visit the SITC (Free SITC Whitepaper) 37th Annual Meeting website, which is available at View Source